Group items tagged

This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

The Neuroendocrine Tumor Research Foundation-AACR Grant represents a joint effort to promote and support innovative cancer research. This grant is available to independent junior and senior investigators to develop and study new ideas and innovative approaches that have direct application and relevance to neuroendocrine tumors. Proposed research may be in any discipline of basic, translational, clinical, or epidemiological cancer research. Applications are invited from researchers currently in the field as well as investigators with experience in other areas of cancer or biomedical research who have promising ideas and approaches that can be applied to neuroendocrine tumor research.

The Neuroendocrine Tumor Research Foundation-AACR Grant represents a joint effort to promote and support innovative cancer research. This grant is available to independent junior and senior investigators to develop and study new ideas and innovative approaches that have direct application and relevance to neuroendocrine tumors. Proposed research may be in any discipline of basic, translational, clinical, or epidemiological cancer research. Applications are invited from researchers currently in the field as well as investigators with experience in other areas of cancer or biomedical research who have promising ideas and approaches that can be applied to neuroendocrine tumor research.

The FY19 PRCRP Idea Award with Special Focus supports innovative, untested, high-risk/ potentially high-reward concepts, theories, paradigms, and/or methods in cancer research that are relevant to active duty Service members, Veterans, other military beneficiaries, and the American public. The "Special Focus" of this award mechanism is on exposures, conditions, or circumstances that are unique to the military, disproportionately represented in a military beneficiary population, or may affect force readiness. Cancers or circumstances with cancer risk that may affect the Service members' support system (military families) are of special importance for total mission readiness. The advancement of knowledge in cancer research, patient care, and/or treatment options in the Military Health System (MHS) is critical to active duty Service members, Veterans, other military beneficiaries, and the American public. Relevance to military health should be articulated with respect to the overall MHS, the FY19 PRCRP Military Health Focus Areas in Section II.A.2, and the mission of the DHP and the FY19 PRCRP.

The Pancreatic Cancer Action Network is accepting applications for its 2018 Catalyst Grant program. The program, which aims to encourage and support junior faculty in the pursuit of pancreatic cancer research and establish a career path in the field, provides grants of up to $500,000 over three years to junior investigators who have yet to secure their first significant research funding. Research projects may be basic, translational, clinical, or epidemiological in nature but must have direct applicability and relevance to pancreatic cancer. Grant recipients not only receive financial support for their funded research but also are invited to join the network's Community for Progress, a mentorship program that works to advance the goal of increasing survival rates and improving outcomes for pancreatic cancer patients. To be eligible, applicants must have a doctoral degree (PD, MD, DO, DC, ND, DDS, DVM, ScD, DNS, PharmD, or equivalent) in the biomedical sciences (or in a field applicable to health science research) and not currently be a candidate for a further doctoral degree. In addition, at the start of the grant term on July 1, 2018, applicants must hold a faculty position with the title of assistant professor, instructor, research assistant professor, or the equivalent.

This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. Furthermore, all research projects must be focused upon knowledge of human biology with a translational human endpoint proposed. All P20 grants must include a minimum of two well-developed translational research projects, as well as contribute significantly to the development of specialized shared resources core facilities, improved research model systems, and collaborative research activities with other institutions, P20 awardees, and/or current SPORE grantees

The aim of the 2018 Bladder Cancer Research Innovation Award is to support exceptionally novel and creative projects with great potential to produce breakthroughs in our understanding or the management of bladder cancer. The proposed research may be basic, translational, or clinical but must have direct applicability and relevance to bladder cancer and address one of the questions of interest (see below). Proposals for innovative projects that will develop preliminary data necessary to prepare and submit a competitive research grant application to a major funding agency are encouraged. The award is available to full time, independent investigators who are affiliated with a non-profit academic, medical or research institution within the United States or Canada. Candidates not currently performing bladder cancer research are encouraged to apply. Proposals that involve a multidisciplinary approach and/or multi-institutional collaboration are encouraged. The award is for $300,000 over two years ($150,000 per year) for direct research expenses, which may include salary and benefits for postdoctoral or clinical research fellows, and/or research assistants; research/lab supplies; and equipment. The second year of funding is dependent on approval after a one year progress report has been submitted and reviewed by BCAN.

This funding opportunity announcement (FOA) is a continuation of Cancer Intervention and Surveillance Modeling Network (CISNET - https://cisnet.cancer.gov) program. This FOA invites applications for collaborative research projects using simulation and other modeling techniques for specific cancer types (see below). The proposed research is expected to generate sophisticated, evidence-based decision tools that could inform international/national/regional/local decisions on the most efficient utilization of existing and emerging technologies and strategies for the control of cancer

Grants are made by the Board of Trustees of Ohio Cancer Research taking into account studies and recommendations of the Scientific Review Committee. Grants are available to investigators in either nonprofit or for-profit institutions, offices or clinics within the State of Ohio. However, grants to investigators working for profit-making organizations may not include funds for capital equipment. Grants are made with the stipulation of their use by a particular individual or group who are known as the principal investigator in support of a specific program of research under his/her/their direction. Full professors or their equivalent are not eligible. Only tenure track, junior faculty or equivalent scientific staffs are generally considered as appropriate. Postdoctoral fellows, Research, research assistants, and graduate students are ineligible to apply as P.I.'s, but they may be included as support staff. The P.I. must show evidence of independence. Applicants must be within six years of their first independent research or faculty appointment. Well established investigators should not submit projects related to their current area of research. Investigators previously funded by Ohio Cancer Research must provide justification that this application is significantly different from the previously funded project. Information regarding the results of the previously funded proposal and the P.I.'s success in obtaining further national funding must also be provided. Grants awarded by Ohio Cancer Research are made to support research activities broadly related to cancer and leukemia. Certain types of projects are not recommended for support. Among these are purely clinical work of a non-research nature and requests for the sole purpose of equipping a laboratory.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions Initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Also listed under R01.

Since its founding in 1979, the Skin Cancer Foundation has set the standard for educating the public and the medical community about skin cancer. The foundation is committed to reducing the incidence and mortality of the world's most common cancer, which is now occurring at epidemic levels. As part of this mission, the foundation is accepting proposals for its 2019 Research Grants Awards program. Two grants of $50,000 and one grant of $25,000 will be awarded to support one-year pilot research projects related to the disease. Researchers are invited to submit applications for projects to be conducted within the dermatology departments of medical institutions in the United States and Canada. The program is open to dermatology residents, fellows, and junior investigators.

REISSUE of PAR-18-733 The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The overall goal of the Gabriella Miller Kids First Pediatric Data Resource is to help researchers understand the underlying mechanisms of these conditions, leading to more refined diagnostic capabilities and ultimately more targeted therapies, as well as to develop an integrated pediatric research data resource by obtaining and aggregating genome sequence and phenotype data for as many relevant structural birth defects and pediatric cancer cohorts as possible and to advance research in this area through the broad sharing of these data with the research community. This FOA is intended to promote meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.

Woman to Woman, a program of the Ovarian Cancer Research Fund Alliance, pairs gynecologic cancer patients with trained survivor-volunteers who provide one-on-one emotional support and mentoring to women when they need it most. From the moment of diagnosis through the end of treatment, Woman to Woman survivor-volunteers have helped hundreds of women and their families cope with gynecologic cancer. Through the program, one-year grants of either $60,000 (for hospital-based programs) or $30,000 (for community-based organizations) will be awarded to institutions with a large volume of gynecologic cancer patients and a need to provide this type of support to patients. Grants are provided to cover the cost of a part-time program coordinator's salary (can be a new hire or a reassignment), program costs, and a patient fund (no indirect costs allowed). It is expected that each Woman to Woman program will become self-sustaining after the first year. OCRFA will provide all program materials for patients, as well as technical assistance and support, for the life of the program (even after the end of the grant period). Institutions and organizations also will have access to a dedicated section of the Woman to Woman website (under construction) featuring tools designed to assist them in the development and administration of new programs.

The Mark Foundation for Cancer Research funds groundbreaking research integrating discoveries in biology with innovative technology to deliver breakthroughs to patients. To advance this mission the foundation is inviting proposals for its Emerging Leaders Awards program, which provides support to early career investigators conducting high impact, high-risk cancer research. Through the annual program, the foundation will award three-year, $750,000 grants to promising early career scientists conducting high-impact, high-risk cancer research. This award is intended to support projects for which other sources of funding are not readily available from traditional funding mechanisms or for a separate innovative endeavor that will enhance the Principal Investigator's current research portfolio. Eligible applicants must hold an M.D., Ph.D., M.D./Ph.D., or equivalent at a U.S. nonprofit academic institution who are within three to eight years from initial independent appointment. In addition, applicants must have a demonstrated ability to obtain independent funding for their lab (e.g., one or two grants such as NIH/R01, NSF/CAREER, or equivalent multi-year awards).

The purpose of this funding opportunity announcement (FOA) is to establish an institutional program for mentored training in global cancer research. This program will support research training led by US-based cancer research-intensive institutions working in collaboration with institutions in low and middle-income countries (LMICs). These training programs will be built upon the US institutions pre-existing training infrastructure and research collaborations with LMICs and will leverage these resources to expand the global cancer research workforce both in the US and in LMICs. The overarching goal of this grant program is to build capacity to conduct innovative and collaborative global research projects that will contribute to the advancement of basic, clinical, translational, and population-based cancer research.

The overall goal of the BHSA is to advance behavioral health cancer science and fill gaps in the understanding of survivorship, including investigations into the psychological health and well- being of those affected by cancer (e.g., patients, family members). This may include investigations into studies that improve mental health and/or cancer related outcomes in defined populations. Studies also may assess the relationship(s) between behavioral and social functioning in relation to cancer initiation, progression, detection, treatment, and rehabilitation. Applications may propose behavioral science that examines quality of life studies, decision making and/or cognitive function research, development and testing of educational interventions, and symptom management (e.g., toxicity of treatment, palliative care, psychological distress and anxiety). Applications may target development of evidence-based practices, behavioral health science interventions and surveillance, and identification of psychosocial patient outcomes.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.